VEGFA and hepatocellular carcinoma: Immunotherapy with atezolizumab (a; anti-programmed death-ligand 1 [PD-L1] antibody) and bevacizumab (b; anti-vascular endothelial growth factor [VEGF] antibody) has significantly improved prognosis of patients with unresectable HCC relative to sorafenib yielding a median overall survival (OS) of 19.2 months.[3], [4], [5] Thus, a + b is currently one of the recommended first-line (1L) systemic treatments for patients with uHCC.6